ADVANCE Praise

Sometimes an artfully crafted quasi-acronym can help distinguish one otherwise indistinguishable clinical advance from another (1–3). The infectiousness of this engaging wordplay is evidenced by a recent report describing the role of Tirofiban for prevention of ischemic complications among high-risk patients undergoing coronary angioplasty (4)—a distinguished advance indeed!

*George A. Diamond, MD, FACC
*2408 Wild Oak Drive
Los Angeles, CA 90068
E-mail: gadiamond@pol.net

REFERENCES


REPLY

We thank Dr. Diamond for his interest in our recent paper (1). It can happen that, when a trial is designed, not enough attention is paid to the (quasi)-acronym used to identify the study. Unfortunately, it also happens that the medical world finishes paying more attention to it than to the trial message itself, and that is not a distinguished advance indeed! But the lesson is clear: from now on, we will keep ADVANCEing with new STRATEGY (2).

*Marco Valgimigli, MD
Patrick W. Serruys, MD, PhD, FACC
*University of Ferrara
Cardiovascular Institute
Arcispedale S. Anna Hospital
Corso Giovecca 203
44100 Ferrara
Italy
E-mail: vlmgmrc@unife.it

REFERENCES


CORRECTION


The correct authors' names are Massimo Chessa, MD, PhD, Gianfranco Butera, MD, PhD, and Mario Carminati, MD.